Erythropoietin Drugs Market to Grow US$ 11.9 Billion by 2026
Pune, Maharashtra, India, February 8 2021 (Wiredrelease) Allied Analytics –:Allied Market Research published a new report, titled, “Global Erythropoietin Drugs Market is expected to garner $11.9 billion by 2020, registering CAGR of 9.7% during the forecast period 2017 – 2026.
Rising incidences of Cancer, ESRD (End Stage Renal Disease), and HIV have largely contributed to the overwhelming demand for EPO drugs. Approximately 20% of the patients suffering from Cancer/HIV and ~70% of the patients suffering from ESRD undergo chemotherapy, which induces anemia in such patients, requiring EPO treatment. Despite this, the market has nevertheless witnesses restraints due to highly priced EPO drugs resulting in minimal adoption. However, commercialization of EPO biosimilars would eventually ease the influence of restraints and fuel the market growth, primarily across the developing regions.
Click Here To Access Sample Report: https://www.alliedmarketresearch.com/request-sample/59
Globally, ~70% of the market share is held by the developed regions owing to favorable reimbursements leading to affordability for EPO drugs. Going forward, owing to commercialization of EPO biosimilars, the Asia-Pacific EPO drugs market would be the most potential market among other regions.
• Due to the global pandemic all over the world, the medical devices manufacturers are majorly focusing on essential medical devices production including ventilators and diagnostics.
• However, due to the precautionary measures taken by governments in various regions, the supply chain has been hampered. Which may result in shortage of devices in certain locations.
• Food and Drugs Administration (FDA), on the other hand, shared a COVID-19 guidance with medical device manufacturers to notify the agency about changes that could affect availability of their products.
Key findings of Erythropoietin Drugs Market:
Europe led the global EPO drug market in 2013 closely followed by North America
Asia Pacific EPO drugs market is projected to grow at a CAGR of 13.3% during the forecast period, fastest among the four geographies
Currently, Anemia therapeutics (Cancer and HIV treatment) market leads the overall EPO drugs market; however, kidney therapeutic segment would emerge as the largest market segment by 2020
Originator companies are investing in R&D for expanding product i.e. EPO drug applications to newer disorders such as neural diseases and in wound healing
EPO drugs market is witnessing high commercialization of biosimilars for the ‘off-patent’ drug namely Erythropoietin alfa.
For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/59
Based on the applications, the global EPO drugs market is segmented into anemia associated with End Stage Renal Diseases (ESRD), cancer chemotherapy and, antiretroviral treatment (ART). Current research is focused toward expanding the applications of EPO drugs in other disease conditions such as neural diseases and wound healing.
Global Erythropoietin drugs market is segmented based on geography into North America, Europe, Asia Pacific and LAMEA. Europe is the leading geographical market owing to favorable reimbursement policies and less stringent and speedy regulatory approvals for EPO drugs.
To view the report, visit the website at http://www.alliedmarketresearch.com/erythropoietin-market
Key companies profiled in the report are, Amgen Inc., Johnson & Johnson, Hospira Inc., Roche, LG Life Sciences Ltd., Biocon, Intas Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Ranbaxy Laboratories Ltd., and Celltrion, Inc.
Similar Reports With COVID-19 Impact:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Portland, OR, United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
This content has been published by Allied Analytics company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at firstname.lastname@example.org.